Gaithersburg-based Emergent BioSolutions has been on a bit of a buying spree lately. On Wednesday, the company announced it would acquire a drug for treating inhaled anthrax from pharmaceutical giant GlaxoSmithKline in an all-cash deal worth up to $96 million. The deal came less than a week after Emergent (NYSE: EBS) announced it would buy French pharmaceutical giant Sanofi’s smallpox vaccine business in an all-cash deal worth up to $125 million. “People have been waiting for acquisitions from…
from https://www.bizjournals.com/baltimore/news/2017/07/21/emergent-biosolutions-acquires-glaxosmithkline.html?ana=RSS%26s=article_search
via http://baltimorecheckbook.tumblr.com/post/163249243382
No comments:
Post a Comment